Wainwright raises Genmab PT to $50; keeps Buy
H.C. Wainwright raised its price target on Genmab to $50 from $40 and maintained a Buy rating, citing positive Phase 3 trial results for Epkinly plus R-CHOP versus R-CHOP in first-line diffuse large B-cell lymphoma patients.